At a Glance
Dosage
Only in 25D-NBOMe
sublingual
| Level | Dose |
|---|---|
| Threshold | 300 µg |
| Light | 300–800 µg |
| Common | 800–1000 µg |
| Strong | 1000–1200 µg |
| Heavy | 1200 µg |
Only in 1cP-MiPLA
oral
| Level | Dose |
|---|---|
| Threshold | 50 µg |
| Light | 100–150 µg |
| Common | 150–200 µg |
| Strong |
Duration
Only in 25D-NBOMe
sublingual
Total: 4 hrs – 6 hrsOnset
Peak
Offset
Onset20 min – 40 min
Peak1 hrs – 2 hrs
Offset1 hrs – 2 hrs
Only in 1cP-MiPLA
oral
Total: 4 hrs – 6 hrsCome Up
Effects
Safety
Interaction: 25D-NBOMe + 1cP-MiPLA
No direct interaction data available between these substances. This does not mean the combination is safe.
25D-NBOMe — Dangerous Interactions
No dangerous interactions recorded.
1cP-MiPLA — Dangerous Interactions
No dangerous interactions recorded.
Frequently Asked Questions
What is the difference between 25D-NBOMe and 1cP-MiPLA?
25D-NBOMe is classified as a Psychedelic (Substituted phenethylamines) while 1cP-MiPLA is classified as a Psychedelic (Lysergamides). They share 45 effects in common, with 21 effects unique to 25D-NBOMe and 25 unique to 1cP-MiPLA.
Is it safe to combine 25D-NBOMe and 1cP-MiPLA?
There is no direct interaction data available for combining 25D-NBOMe and 1cP-MiPLA. This does not mean the combination is safe. Always exercise caution and research thoroughly.
Which is stronger, 25D-NBOMe or 1cP-MiPLA?
25D-NBOMe and 1cP-MiPLA are typically administered via different routes, making a direct potency comparison difficult. They belong to different pharmacological profiles and should not be compared by dose alone.